Advertisement
Home Tags Hormones: Male

Tag: Hormones: Male

Testosterone Treatment Does Not Cut Fracture Incidence in Men With Hypogonadism

Findings show no reduction in clinical fracture among middle-aged, older men with hypogonadism

Hematocrit Within Normal Range With Testosterone Gender-Affirming Therapy

Mean hematocrit ranged from 41.84 to 45.68 percent for those receiving testosterone as gender-affirming hormone therapy

Testosterone Efficacious for Correcting Anemia in Middle-Aged Men

Fewer men without anemia developed anemia with testosterone replacement therapy versus placebo

Multiple Factors Associated With Sex Hormone Variation in Men

Testosterone levels appear to decline among men older than 70 years; inverse link seen for testosterone with BMI

Effect of Testosterone Examined From Adolescence Into Adulthood

Effect of testosterone on anterior prefrontal cortex engagement decreases from middle-to-late adolescence, then shifts into activational role

ENDO: Testosterone-Replacement Noninferior to Placebo for Cardiovascular Events

Findings seen in middle-aged men with preexisting or high risk of cardiovascular disease and hypogonadism

Direct-to-Consumer Testosterone Not Offered in Accordance With Guidelines

Most direct-to-consumer platforms offer testosterone therapy despite consumer reporting normal testosterone levels, free testosterone

Standard Testosterone Threshold Not Accurate for Younger Men

Age-specific testosterone cutoffs show each one-year increase in age tied to a 4.3-ng/dL decrease in testosterone level

COVID-19 Hospitalization Risk Higher for Men With Hypogonadism

Odds of hospitalization higher for men receiving inadequate TTh versus those with normal testosterone concentration while receiving TTh

Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk

No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety